Rachel is an accomplished expert in metabolomics with over 10 years of mass spectrometry experience. Her previous research focused on studying metabolic alterations in various disease states, including acute myeloid leukemia, Down Syndrome, sickle cell disease, breast cancer, and hemorrhagic shock. Her groundbreaking work on understanding the complex metabolome of acute myeloid leukemia stem cells and other cancers has been published in scientific journals such as Nature Medicine, Nature Cancer, Cell, Cancer Cell, Cell Stem Cell, Blood, and more.
At AOA Dx, Rachel dedicates her expertise to validating a diagnostic test for ovarian cancer and expanding the GlycoLocateTM platform to detect additional cancer targets. Her commitment to cancer diagnostics and prevention fuels her drive to solve challenging problems in the field.
Rachel earned her Ph.D. in Biochemistry from the University of Colorado Anschutz Medical Campus and holds an M.Sc. in Microbiology from the University of Florida, along with a B.S. in Biochemistry and Molecular Biology from Michigan State University. With her multidisciplinary knowledge, scientific acumen, and proven track record, Rachel continues to push the boundaries of cancer research, contributing to advancements in detection and treatment methods.